French IVD (in vitro diagnostic) market shows healthy 7.5% growth in 2003
This article was originally published in Clinica
Executive Summary
The value of the French IVD market rose well above the increase in inflation in 2003, by 7.5% over the previous year to reach Euros1.33bn ($1.59 bn). Reagents accounted for Euros1.1bn of this total, and instruments for the remaining Euros227m, according to the French IVD industry association, SFRL.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.